SPECTRUM OF BRAIN ABNORMALITIES DETECTED ON WHOLE BODY F-18 FDG PET/CT SCAN

Authors

  • Aamna Hassan Shaukat Khanum Memorial Cancer Hospital and Research Center
  • Yasir Majeed Shaukat Khanum Memorial Cancer Hospital and Research Center
  • Khurram Aftab Shaukat Khanum Memorial Cancer Hospital and Research Center

Abstract

Positron emission tomography (PET) with integrated computed tomography (CT) is a unique modality to noninvasively scan the whole body for diagnosing, staging and assessing response to therapy in various benign and malignant diseases. 18F fluorodeoxyglucose (FDG) is the most commonly used radiotracer for PET/CT imaging in cancer patients. FDG is a glucose analogue which is the predominant substrate for brain metabolism. As the brain cells are obligate glucose consumers, the knowledge of physiologic radiotracer uptake within the brain is imperative for correct interpretation of abnormal sites of metabolism. Over 10,000 PET/CT scans have been performed at our centre in a 5 years’ period. A spectrum of brain abnormalities, both benign and malignant, detected in cancer patients undergoing whole body 18F FDG PET/CT imaging has been compiled.Keywords: Fluorodeoxyglucose; Positron Emission Tomography; Computed Tomography; Magnetic Resonance Imaging; Brain Tumours, Brain Metastasis; Benign Cerebral Lesions

Author Biographies

Aamna Hassan, Shaukat Khanum Memorial Cancer Hospital and Research Center

Nuclear Medicine DepartmentConsultant Nuclear Physician

Yasir Majeed, Shaukat Khanum Memorial Cancer Hospital and Research Center

Nuclear Medicine DepartmentFellow PET/Nuclear Medicine

Khurram Aftab, Shaukat Khanum Memorial Cancer Hospital and Research Center

Consultant RadiologistRadiology Department

References

Berti V, Mosconi L, Pupi A. Brain: Normal Variations and Benign Findings in FDG PET/CT imaging. PET Clin 2014;9(2):129–40.

Kochunov P, Ramage AE, Lancaster JL, Robin DA, Narayana S, Coyle T, et al. Loss of cerebral white matter structural integrity tracks the gray matter metabolic decline in normal aging. Neuroimage 2009;45(1):17–28.

Stewart BW, Wild C, International Agency for Research on Cancer, World Health Organization, editors. World cancer report 2014. Lyon, France: International Agency for Research on Cancer; 2014.

Di Chiro G. Positron emission tomography using [18F] fluorodeoxyglucose in brain tumours: A powerful diagnostic and prognostic tool. Invest Radiol 1987;22(5):360–71.

Spence AM, Muzi M, Graham MM, O'Sullivan F, Krohn KA, Link JM, et al. Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: Analysis of the FDG lumped constant. J Nucl Med 1998;39(3):440–8.

Kim YS, Kondzielka D, Flicklligar JC, Lunsford LD. Stereotactic radiosurgery for patients with non-small cell lung cancer metastatic to the brain. Cancer 1997;80(11):2075–83.

Young RF. Radiosurgery for the treatment of brain metastases. Semin Surg Oncol 1998;14(1):70–8.

Rock RB, Olin M, Baker CA, Molitor TW, Peterson PK. Central nervous system tuberculosis: pathogenesis and clinical aspects. Clin Microbiol Rev 2008;21(2):243–61.

Kamaleshwaran KK, Shinto AS, Natarajan S, Mohanan V. F-18 FDG PET/CT in Tuberculosis: Non-Invasive Marker of Therapeutic Response to Antitubercular Therapy. Int J 2015;2(1):23.

Skoura E, Zumla A, Bomanji J. Imaging in tuberculosis. Int J Infect Dis 2015;32:87–93.

Ankrah AO, van der Werf TS, de Vries EF, Dierckx RA, Sathekge MM, Glaudemans AW. PET/CT imaging of Mycobacterium tuberculosis infection. Clin Transl Imaging 2016;4:131–44.

Downloads

Published

2017-01-25